Drug intelligence / Profile preview

clomipramine + tandospirone

Development stage: Unknown
Lead developer: Sumitomo Pharma
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy using clomipramine, a tricyclic antidepressant, with tandospirone, an azapirone anxiolytic and antidepressant, as an augmentation strategy. Clomipramine works primarily as a serotonin reuptake inhibitor while tandospirone acts as a selective 5-HT1A receptor partial agonist. This combination has been studied for treating major depressive disorder, with some evidence suggesting tandospirone may induce earlier antidepressant effects when used to augment clomipramine treatment.

Targets

HTR2B (5-Hydroxytryptamine Receptor 2B)5-HT2C (5-hydroxytryptamine receptor 2C)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on clomipramine + tandospirone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clomipramine + tandospirone.

Explore the full profile